Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on MNPR. Piper Sandler set a $105.00 target price on Monopar Therapeutics in a report on Tuesday, June 2nd. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $109.00 to $119.00 in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.42.

Monopar Therapeutics Trading Up 2.4%

Shares of Monopar Therapeutics stock opened at $113.04 on Thursday. The company has a fifty day moving average price of $96.11 and a 200 day moving average price of $71.53. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82. The stock has a market cap of $757.25 million, a price-to-earnings ratio of -52.09 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. Analysts forecast that Monopar Therapeutics will post -2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new position in Monopar Therapeutics during the 2nd quarter worth $7,124,000. Bank of America Corp DE lifted its position in shares of Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Monopar Therapeutics in the first quarter worth about $250,000. Finally, Siren L.L.C. increased its holdings in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.